Eli Lilly & Company

Type: Company
Name: Eli Lilly & Company (Eli Lilly and Company)
First reported 23 hours ago - Updated 47 mins ago - 22 reports

Lilly’s ixekizumab shows superiority over etanercept and placebo in Ph III

US pharma major Eli Lilly’s (NYSE: LLY) investigational medicine ixekizumab was superior to etanercept and placebo on all skin clearance measures in Phase III studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies ... [Published Pharma Letter - 47 mins ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Broomfield's Corgenix partners with Eli Lilly on diagnostic product

Corgenix Medical Corp., a Broomfield-based developer of diagnostic products including tests to rapidly detect deadly viruses such as Ebola, has entered into a technology transfer, licensing and development agreement with Eli Lilly and Company, regulatory ... [Published Boulder Daily Camera - 9 hours ago]
First reported 17 hours ago - Updated 17 hours ago - 1 reports

Emerging Pharma Leaders 2014

This year's class of 15 young executives is deeply of the moment, with assignments that include advancing therapies againsthepatitis C, building new cell-based platforms in regenerative medicine, creating new businesses beyond a protected home base,restructuring ... [Published Pharmaceutical Executive - 17 hours ago]
First reported 18 hours ago - Updated 18 hours ago - 1 reports

Plans for new homes on former Eli Lilly site to be decided next week

NEARLY 600 new homes could be built on the former Eli Lilly site if Basingstoke and Deane Borough Council give the go ahead to the scheme next week.Sentinel Housing Association and Vestal Developments Limited applied to the borough council for outline ... [Published Basingstoke Gazette - 18 hours ago]
First reported Aug 20 2014 - Updated 18 hours ago - 2 reports

Box Powers Cloud Collaboration for Leading Life Sciences Organizations

LOS ALTOS, Calif.--(BUSINESS WIRE)--Box today announced that leading pharmaceutical and life sciences organizations Jazz Pharmaceuticals and Boston Scientific Corporation have recently chosen Box as their primary platform for managing and collaborating ... [Published Business Wire Technology News - Aug 20 2014]
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Emerging Pharma Leaders: Michael Injaychock, Eli Lilly & Co.

Michael Injaychock  joined Eli Lilly in 2007 after five years in a Washington-based financial services consulting role and a subsequent MBA from the University of North Carolina. Course work there as well as a stiff self-evaluation of his former job led ... [Published Pharmaceutical Executive - 19 hours ago]
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Pharma Stocks Review -- Eli Lilly, Zogenix, GlaxoSmithKline, Novo Nordisk, and Valeant Pharma Intl.

/PRNewswire/ --The trading session on Wednesday, August 20, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,979.13, up 0.35% and the NASDAQ Composite closed at 4,526.48, down 0.02%. The S&P 500 finished the day 0.25% higher ... [Published TickerTech.com - 20 hours ago]
First reported Aug 20 2014 - Updated 22 hours ago - 1 reports

Box powers mobile content-sharing for sales people and others at major pharmaceutical firms

A number of major pharmaceutical companies have adopted Box for file-sharing between computers and their fast-growing deployments of iPads, particularly to their sales force.Silicon Valley-based Box just announced that Jazz Pharmaceuticals and Boston ... [Published Tab Times - Aug 20 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Today's Post-Market Laggard: Eli Lilly And (LLY)

If your browser does not automatically forward you to http://business-news.thestreet.com/philly/story/todays-post-market-laggard-eli-lilly-and-lly/12852244, please click here. ... [Published Philly.com - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 21 2014 - 6 reports

ELI LILLY : Trademark Application for "NEFRENE" Filed by Eli Lilly

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a trademark application has been made for "NEFRENE" by Bruce W. Longbottom , representing Eli Lilly ... [Published 4 Traders - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 4 reports

Lilly, Boehringer Ingelheim Get Tentative FDA OK For Basaglar

By Estel Grace MasangkayEli Lilly together with its partner Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Basaglar (insulin glargine injection) indicated for the improvement of glycemic ... [Published Bioresearch Online - Aug 20 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Boehringer and Eli Lilly receive FDA approval for type 2 diabetes drug

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company have received the FDA approval for Jardiance tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes, or T2D. ... [Published Individual.com - Aug 20 2014]

Quotes

"These results give us confidence that if approved, ixekizumab could make complete resolution of psoriasis possible for significantly more people" he said. In contrast, Enbrel achieved clear skin in just 5 to 7 per cent of patients
"These data are important for people suffering from moderate-to-severe plaque psoriasis, as up to 41 percent of those treated with ixekizumab were able to achieve clear skin at week 12, with just one injection per dose. These results give us confidence that if approved, ixekizumab could make complete resolution of psoriasis possible for significantly more people" said David Ricks, Lilly senior vice president, and president, Lilly Bio-Medicines
"When we get into a project like this, the opportunity is well into the future" he said
"Astra will ask for much more, and they have proven they are building a very solid pipeline," Helvea analyst Odile Rundquist told Bloomberg . "My impression is that the deal will never go through, because it is too expensive for Pfizer." Other analysts have suggested GlaxoSmithKline GSK ) as an alternative target, but even after its recent share price drop its market cap is near £70 billion...

More Content

All (1857) | News (1337) | Reports (0) | Blogs (468) | Audio/Video (0) | Fact Sheets (18) | Press Releases (28)
sort by: Date | Relevance
Lilly’s ixekizumab shows superiority over etane... [Published Pharma Letter - 47 mins ago]
Lilly's psoriasis candidate tops Enbrel in phas... [Published PMLive - 52 mins ago]
Eric A. Rubel, Partner, Arnold & Porter LLP to ... [Published PR.com Press Releases - 3 hours ago]
Phage therapy could benefit poultry health [Published Farmers Weekly Interactive - 4 hours ago]
Panitumumab With FOLFOX4 for Treatment of Metas... [Published General Medicine eJournal - 5 hours ago]
Eli Lilly's ixekizumab superior to etanercept a... [Published PharmaBiz - 6 hours ago]
Broomfield's Corgenix partners with Eli Lilly o... [Published Boulder Daily Camera - 9 hours ago]
Lilly takes on Amgen's Enbrel [Published Medical Marketing And Media - 11 hours ago]
Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly ... [Published Jutia Group - 12 hours ago]
AZ may be too expensive for Pfizer, Orexo to up... [Published FierceBiotech - 12 hours ago]
Bristol-Myers, Celgene Pair Up for Oncology Com... [Published Zacks.com - 13 hours ago]
Ixekizumab shows superiority to etanercept in p... [Published Orthopedics Today - 14 hours ago]
Promising Superbug Remedies Make Cubist a Prime... [Published Pharmaceutical Manufacturing Magazine - 14 hours ago]
Eli Lilly says psoriasis drug aced its late-pha... [Published Indianapolis Star - 15 hours ago]
Stock Update: Eli Lilly & Company (NYSE:LLY) – ... [Published Renewable Energy World - 15 hours ago]
UPDATE 2-Lilly psoriasis drug impresses; battle... [Published Reuters - 16 hours ago]
Emerging Pharma Leaders 2014 [Published Pharmaceutical Executive - 17 hours ago]
Lilly's strong results for psoriasis drug come ... [Published FiercePharma - 17 hours ago]
Local West Africans Fighting Ebola with help fr... [Published Myrtle Beach Sun News - 17 hours ago]
Local West Africans Fighting Ebola with help fr... [Published Stock Nod - 17 hours ago]
Plans for new homes on former Eli Lilly site to... [Published Basingstoke Gazette - 18 hours ago]
Lilly to Seek Approval For Psoriasis Drug [Published Inside INdiana Business - 18 hours ago]
Emerging Pharma Leaders: Michael Injaychock, El... [Published Pharmaceutical Executive - 19 hours ago]
Lilly Says Ixekizumab Superior To Etanercept/Pl... [Published RTTNews.com - 19 hours ago]
Lilly psoriasis drug fares well in late-stage test [Published Crawford Financial Planning - 20 hours ago]
Allianz streamlines medical-claims submissions ... [Published Mobile Commerce Daily - 20 hours ago]
Pharma Stocks Review -- Eli Lilly, Zogenix, Gla... [Published TickerTech.com - 20 hours ago]
Pharma Stocks Review -- Eli Lilly, Zogenix, Gla... [Published Financial Services - 20 hours ago]
Lilly psoriasis treatment beats placebo in stud... [Published MedCity News - 21 hours ago]
Lilly joins the list of Enbrel-beaters with hea... [Published FierceBiotech - 21 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eric A. Rubel, Partner, Arnold & Porter LLP to ... [Published PR.com Press Releases - 3 hours ago]
New York, NY, August 22, 2014 --( PR.com )-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Eric A. Rubel, Partner, Arnold & Porter LLP will speak at the ...
Eli Lilly (LLY) Trading Near $62.54 Resistance ... [Published MarketIntelligenceCenter.com - 22 hours ago]
Eli Lilly and Co (LLY) is a good candidate for a covered call at the $62.50 level. The Oct. '14 call at that price should fetch a credit of about $1.28, which means the entire position has a net debit of about $60.73. This trade has 1.92% downside protection. ...
Box Powers Cloud Collaboration for Leading Life... [Published Business Wire Technology News - Aug 20 2014]
LOS ALTOS, Calif.--(BUSINESS WIRE)--Box today announced that leading pharmaceutical and life sciences organizations Jazz Pharmaceuticals and Boston Scientific Corporation have recently chosen Box as their primary platform for managing and collaborating ...
Box Powers Cloud Collaboration for Leading Life... [Published Business Wire Health News - Aug 20 2014]
LOS ALTOS, Calif.--(BUSINESS WIRE)--Box today announced that leading pharmaceutical and life sciences organizations Jazz Pharmaceuticals and Boston Scientific Corporation have recently chosen Box as their primary platform for managing and collaborating ...
Temporary Approval for New Insulin Glargine [Published MedPageToday.com - medical news plus CME for ph ... - Aug 20 2014]
(MedPage Today) -- The FDA has temporarily approved Eli Lilly's "biosimilar" insulin glargine (Basaglar), but it won't be on the market until the company resolves patent litigation with Sanofi. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Pharma Stocks Review -- Eli Lilly, Zogenix, Gla... [Published Financial Services - 20 hours ago]
Drug Approvals & Updates, Licensing Agreements,... [Published Financial Services - Aug 14 2014]
Global Diabetic Neuropathy Market 2014-2018: Ke... [Published GlobeNewswire: Advertising News - Aug 07 2014]
Critical Alerts For Groupon, Gilead Sciences, B... [Published Financial Services - Aug 04 2014]
Biotechnology Sector Trends Higher with Breakth... [Published Financial Services - Jul 16 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.